MAWAG
RNAM

Mid-American Wealth Advisory Group’s Avidity Biosciences RNAM Stock Holding History

Mid-American Wealth Advisory Group’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20
Closed -$568 – 256
2025
Q2 		$568 Buy
+20
New +$596 ﹤0.01% 309

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mid-American Wealth Advisory Group's RNAM Position: Q3 2025 in Review

Mid-American Wealth Advisory Group sold out of Avidity Biosciences (RNAM) in Q3 2025, closing a stake of 20 shares — an estimated $568 sold.

Mid-American Wealth Advisory Group first reported a position in RNAM in Q2 2025 and held it in 1 quarter. The position peaked at $568 in Q2 2025. 272 funds tracked by Wall St. Rank hold RNAM as of Q3 2025.

  • Mid-American Wealth Advisory Group reported no remaining Avidity Biosciences position as of Q3 2025 after selling out during the quarter.
  • Mid-American Wealth Advisory Group sold 20 Avidity Biosciences shares in Q3 2025, an estimated $568.
  • Mid-American Wealth Advisory Group first reported a position in Avidity Biosciences in Q2 2025 and held it in 1 quarter.
  • Mid-American Wealth Advisory Group's Avidity Biosciences position peaked at $568 in Q2 2025.
  • 272 funds tracked by Wall St. Rank held Avidity Biosciences as of Q3 2025.

Based on Mid-American Wealth Advisory Group's 13F filing for Q3 2025, filed 20 Oct 2025.